ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ProKidney (Nasdaq: PROK), a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), has announced its participation in the H.C. Wainwright 4th Annual Kidney Virtual Conference. The company's management team will engage in a fireside chat on Monday, July 14, 2025, at 1:30 PM ET.
Investors can access the live webcast through the Events section of ProKidney's Investor Relations webpage at www.prokidney.com. One-on-one meetings are available through H.C. Wainwright representatives.
Details
News Market Reaction – PROK
The recorded move for PROK in the trading session of this news was +16.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference:
| H.C. Wainwright 4th Annual Kidney Virtual Conference | |
| Date: | Monday, July 14, 2025 |
| Time: | 1:30pm ET |
| Format: | Fireside Chat |
| Webcast: | Link |
The live webcast will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Investors interested in one-on-one meetings should contact their H.C. Wainwright representative.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.